Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Access of MK-0518 (Isentress / Raltegravir) With Optimized Background Therapy in Highly Treatment-Experienced HIV-1 Patients
2006-003881-32Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of raltegravir in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1, sponsored by Merck & Co. Primary endpoint: Safety and tolerability (APaT population). Started Jan 2007; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-003881-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003881-32.